Australia is eagerly awaiting the introduction of Retatrutide, a novel medication from Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, presents impressive performance in clinical trials, https://faycnfa297915.mappywiki.com/2603545/retatrutide_australia_a_promising_advancement_for_obesity_treatment